NVO held its Investor Day webcast yesterday—lots of interesting slides on the diabetes market, especially as it pertains to The Global Demographic Tailwind:
10% of adults in China are diabetic (#msg-48221898), so there’s a really big upside here for somebody.
Did NVO discuss the ultra-fast acting insulins, either their own candidates or buzz about any desire to in-license such a candidate? I'm now long BIOD and they could sure use a big pharma partner in the diabetes space.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.